Avanir Loss In Line with Ests, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:00PM CDT
Avanir Pharma (AVNR) reported second quarter fiscal 2014 net loss per share of 8 cents, in line with the Zacks Consensus Estimate.
Avanir's Loss Narrows as Nuedexta Revenue Rises
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 4:21PM CDT
Small-cap biopharmaceutical company Avanir Pharmaceuticals continued to showcase its progress to investors today by reporting greatly improved sales and a narrower loss with the release of its second-quarter results after the closing bell. For...
Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results
PR Newswire - Tue May 06, 3:01PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014.
Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri May 02, 8:45AM CDT
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Upgrade Alert for AVANIR Pharmaceuticals (AVNR)
Comtex SmarTrend(R) - Fri May 02, 7:03AM CDT
AVANIR Pharmaceuticals (NASDAQ:AVNR) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $4.65 on volume of 11.7 million shares, above average daily volume of 2.0 million. AVANIR Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases.
Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor.
Avanir Pharmaceuticals (AVNR) Stock Falls Off After Yesterday's Gain
at The Street - Thu May 01, 3:08PM CDT
Avanir Pharmaceuticals (AVNR) spiked Wednesday afternoon after a court ruled in the company's favor in a patent litigation case, but the shares had fallen off considerably by the close of trading Thursday.
Avanir Pharmaceuticals to Participate in Two Conferences in May
PR Newswire - Thu May 01, 3:00PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in May.
Stock to Watch: AVANIR Pharmaceuticals Down 5.0% (AVNR)
Comtex SmarTrend(R) - Thu May 01, 10:40AM CDT
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's worst performing low-priced stocks, down 5.0% to $4.73 on 3.7x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 7.3 million shares, vs. average volume of 2.0 million shares per day. The stock has underperformed the Dow (-5.0% to the Dow's -0.0%) and underperformed the S&P 500 (-5.0% to the S&P's 0.1%) during today's trading.
Pre-Market Scans on Top Gainers -- Research on NQ Mobile, AVANIR Pharma, WellPoint, and Aspen Technology
PR Newswire - Thu May 01, 7:50AM CDT
The US markets saw a positive sentiment on Wednesday, April 30, 2014, with the NASDAQ Composite closing at 4,114.56, up 0.27%, the Dow Jones Industrial Average ending the session 0.27% higher at 16,580.84, and the S&P 500 edging 0.30% higher to finish the trading session at 1,883.95. The recent session welcomed some action on the Materials, Industrials, and Consumer Discretionary sectors that positively impacted the broader market. A number of stocks saw large movements, including NQ Mobile Inc. (NYSE: NQ), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), WellPoint Inc. (NYSE: WLP) and Aspen Technology Inc. (NASDAQ: AZPN). Free technical research on NQ, AVNR, WLP and AZPN can be downloaded upon signing up at:
Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:44AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day.
Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ --
Why Avanir Pharmaceuticals, Pepco, and Level 3 Communications Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 30, 4:15PM CDT
I hope you're a good swimmer, because we were absolutely buried with economic data on this last day of April. The end result was a whipsaw effect in the broad-based S&P 500 , which left it modestly higher for the session. We started the...
Why Avanir Pharmaceuticals (AVNR) Stock Spiked Today
at The Street - Wed Apr 30, 2:21PM CDT
Avanir Pharmaceuticals (AVNR) spiked Wednesday afternoon after the U.S. District Court for the District of Delaware ruled in the company's favor in its patent infringement lawsuit against Par Pharmaceuticals and Impax Laboratories over NUEDEXTA.
Avanir Pharmaceuticals Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026
PR Newswire - Wed Apr 30, 2:04PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company's patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications ('ANDAs'
Avanir Pharmaceuticals Announces Date of Fiscal 2014 Second Quarter Financial Results and Conference Call
GlobeNewswire - Tue Apr 29, 9:29AM CDT
Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended March 31, 2014 after market close on Tuesday May 6, 2014. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the 66th Annual Meeting of the American Academy of Neurology
PR Newswire - Mon Apr 28, 7:30AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology, discussing PBA diagnosis in patients with Alzheimer's disease (AD) and other dementias, will be available at AAN and was recently published online. The AAN presentations and US Neurology publication offer important new insights into the prevalence, diagnosis, impact and treatment of PBA, a distressing neurological condition characterized by uncontrollable laughing or crying. Data from the pivotal phase III trial of AVP-825, an investigational drug-device combination product for the acute treatment of migraine will also be presented.
Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:
Avanir's AVP-825 under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 4:20PM CDT
Avanir Pharmaceuticals announced that the New Drug Application for its migraine candidate, AVP-825, has been accepted by FDA.